Navidea Biopharmaceuticals, Inc. NAVB Requests Oral Hearing With NYSE Hearing Panel
- DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. NAVB Requests Oral Hearing With NYSE Hearing Panel.
- 08/10/2023
|
Navidea Biopharmaceuticals, Inc. Presses Ahead, Embraces Opportunities
- DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. Presses Ahead, Embraces Opportunities.
- 07/31/2023
|
Why Is Navidea Biopharmaceutical (NAVB) Stock Down 13% Today?
- Navidea Biopharmaceutical (NYSEMKT: NAVB ) stock is falling on Monday after the biopharmaceutical company got a major delisting warning. The NYSE American LLC sent the company a notice about its failure to comply with listing standards.
- 07/31/2023
|
Navidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination
- DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination.
- 07/28/2023
|
NYSE American to Commence Delisting Proceedings Against Navidea Biopharmaceuticals, Inc. (NAVB)
- NEW YORK--(BUSINESS WIRE)--NYSE American LLC (“NYSE American” or the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of Navidea Biopharmaceuticals, Inc. (the “Company”) — ticker symbol NAVB —from the Exchange. NYSE Regulation has determined that the Company is no longer suitable for listing pursuant to Section 1009(a) of the NYSE American Company Guide (the “Company Guide”) as the Company was unable to demonstrate t.
- 07/28/2023
|
Navidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as Chief Financial Officer
- DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as Chief Financial Officer.
- 07/27/2023
|
Navidea Biopharmaceuticals, Inc. Welcomes Dana J Moss, JD to Board of Directors; Amit Bhalla Steps Down
- DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced Dana J Moss, JD has joined the Company's Board of Directors, adding depth in legal advice, strategic business, life sciences and technology in line with Navidea's stated objectives and its Fix, Fund, Propel approach to advancing innovative technology to market. Separat.
- 07/13/2023
|
Navidea Biopharmaceuticals rejects ProPhase Labs offer
- Navidea Biopharmaceuticals Inc. NAVB, -2.38% announced Friday that it had rejected an unsolicited ProPhase Labs Inc. PRPH, +0.08% offer for certain Navidea assets, saying the proposal undervalues Navidea and is not in the best interest of shareholders. ProPhase, a biotech, genomics and diagnostics company, said in a release Thursday that on June 8 it had offered $7 million in cash or $9.1 million in common stock for the assets, with the cash offer equivalent to over two times the then-current market cap of Navidea.
- 06/30/2023
|
Navidea Biopharmaceuticals, Inc. Rejects Unsolicited Offer To Acquire Certain Assets
- DUBLIN, Ohio--(BUSINESS WIRE)--Following the Company's Fix, Fund, Propel approach, the proposal substantially undervalues Navidea and is not in the best interests of stockholders.
- 06/30/2023
|
Navidea Biopharmaceuticals, Inc. Announces Distribution of Series K Preferred Stock to Holders of its Common Stock
- DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series K Preferred Stock, par value $0.001 per share, for each outstanding share of the Company's common stock held of record as of 5:00 p.m. Eastern Time on June 27, 2.
- 06/16/2023
|
Navidea Biopharmaceuticals, Inc. Receives $7.5 Million Cash from Cardinal Health in Lieu of Contingent Milestone Payment
- DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. Receives $7.5 Million Cash from Cardinal Health in Lieu of Contingent Milestone Payment.
- 06/16/2023
|
Navidea Biopharmaceuticals, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update
- DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update.
- 06/07/2023
|
Navidea Biopharmaceuticals, Inc. Receives NYSE American Notice
- DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that it received a Notice (the “Notice”) on June 1, 2023 from the NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance with the continued listing standards as set forth in Section 1003(f)(v) of the NYSE American Company Guide (“Company.
- 06/02/2023
|
Navidea Biopharmaceuticals, Inc. Welcomes Jill Bieker Stefanelli, Ph.D. to Board of Directors; Alexander L.
- DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. Welcomes Jill Bieker Stefanelli, Ph.D. to Board of Directors; Alexander L. Cappello Steps Down.
- 06/01/2023
|
Navidea Biopharmaceuticals, Inc. Investors Purchase $1.1 Million in Preferred Shares at Market
- DUBLIN, Ohio--(BUSINESS WIRE)--New Existing Navidea Biopharmaceuticals, Inc. Investors Purchase $1.1 Million in Preferred Shares at Market.
- 05/22/2023
|
Navidea Biopharmaceuticals, Inc. Promotes Michael Sherman Blue, M.D., FACEP, to Chief Medical Officer
- DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. Promotes Michael Sherman Blue, M.D., FACEP, to Chief Medical Officer.
- 05/11/2023
|
Navidea Biopharmaceuticals, Inc. (NAVB) Q4 2022 Earnings Call Transcript
- Navidea Biopharmaceuticals, Inc. (NYSE:NAVB ) Q4 2022 Earnings Conference Call March 22, 2023 5:00 PM ET Company Participants Michael Rosol - SVP & Chief Medical Officer Erika Eves - VP, Finance & Administration and Principal Financial & Accounting Officer Joseph Meyer - Controller Alexander Cappello - Independent Chairman Conference Call Participants Edward English - Private Investor Operator Greetings, and welcome to the Navidea Biopharmaceuticals Fourth Quarter Earnings Call and Business Update. [Operator Instructions].
- 03/21/2023
|
Navidea Biopharmaceuticals, Inc. (NAVB) Q3 2022 Earnings Call Transcript
- Navidea Biopharmaceuticals, Inc. (NYSE:NAVB ) Q3 2022 Earnings Conference Call November 15, 2022 5:00 PM ET Company Participants Michael Rosol – Chief Medical Officer Erika Eves – Vice President-Finance and Administration Conference Call Participants Michael Okunewitch – Maxim Group Mike Rigali – Private Investor Operator Greetings and welcome to the Navidea Biopharmaceuticals' Quarter Three Earnings Call and Business Update. [Operator Instructions] And as a reminder this conference call is being recorded.
- 11/15/2022
|
Navidea Biopharmaceuticals to Host Third Quarter 2022 Earnings Conference Call and Business Update
- DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will host a conference call and webcast on Tuesday, November 15, 2022 at 5:00 p.m.
- 11/04/2022
|
Navidea Biopharmaceuticals, Inc. (NAVB) Q2 2022 Earnings Call Transcript
- Navidea Biopharmaceuticals, Inc. (NYSE:NAVB ) Q2 2022 Earnings Conference Call September 8, 2022 4:00 PM ET Company Participants Michael Rosol – CMO Alex Cappello - Vice Chair Erika Eves - VP, Finance & Administration Conference Call Participants Michael Okunewitch - Maxim Group Fred Zaino - Keystone Michael Okunewitch - Maxim Group Operator Greetings. Welcome to the Navidea Quarter Two 2022 Earnings Call and Business Update.
- 09/08/2022
|
Navidea Biopharmaceuticals Announces Closing of its Rights Offering and Second Quarter 2022 Earnings Conference Call and Business Update
- DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced today the closing of its rights offering and the final results thereof. Navidea received aggregate gross cash proceeds of approximately $6.2 million in the rights offering. If exercised, additional gross proceeds of up to $11.6 million may be received through the exercise of
- 08/30/2022
|
Navidea Biopharmaceuticals, Inc. (NAVB) Management on Q1 2022 Results - Earnings Call Transcript
- Navidea Biopharmaceuticals, Inc. (NYSE:NAVB ) Q1 2022 Results Conference Call May 12, 2022 5:00 PM ET Company Participants Michael Rosol - CMO Erika Eves - VP, Finance & Administration Conference Call Participants Michael Okunewitch - Maxim Group Operator Welcome to the Navidea Biopharmaceuticals First Quarter 2022 Earnings Call and Business Update. I will now turn the call over to the Chief Medical Officer from Navidea, Michael Rosol, you may begin.
- 05/12/2022
|
Navidea Biopharmaceuticals, Inc. (NAVB) Q4 2021 Results - Earnings Call Transcript
- Navidea Biopharmaceuticals, Inc. (NAVB) Q4 2021 Results - Earnings Call Transcript
- 03/23/2022
|
Navidea Biopharmaceuticals, Inc. (NAVB) Q3 2021 Results - Earnings Call Transcript
- Navidea Biopharmaceuticals, Inc. (NAVB) Q3 2021 Results - Earnings Call Transcript
- 11/11/2021
|
Navidea Biopharmaceuticals Appoints Thomas Forest Farb-Horch and Agnieszka Winkler to the Board of Directors
- DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the appointment of Thomas Forest Farb-Horch and Agnieszka Winkler to its Board of Directors, effective October 7, 2021, each with a three-year term ending concurrently with the Company's 2024 annual stockholders' meeting. Thomas Forest Farb-Horch has over three decades
- 10/14/2021
|
Navidea Biopharmaceuticals Appoints Michel Mikhail, Ph.D. as Chief Regulatory Officer
- DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the appointment of Michel Mikhail, Ph.D. as Chief Regulatory Officer of Navidea, effective October 1, 2021. Dr. Mikhail has more than 30 years of experience in the pharmaceutical industry and a track record of achievement in R&D and international regulatory affairs
- 09/27/2021
|
Navidea Biopharmaceuticals Announces Changes to Board of Directors Composition
- DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that on September 14, 2021, at a meeting of the Board of Directors (the “Board”) of the Company that followed the Company's 2021 Annual Meeting of Stockholders, S. Kathryn Rouan, Ph.D. retired as Chair of the Board and as a director, and Claudine Bruck, Ph.D. retired a
- 09/17/2021
|
Navidea Biopharmaceuticals, Inc. (NAVB) CEO Jed Latkin on Q2 2021 Results - Earnings Call Transcript
- Navidea Biopharmaceuticals, Inc. (NAVB) CEO Jed Latkin on Q2 2021 Results - Earnings Call Transcript
- 08/11/2021
|
Navidea Biopharma (NAVB) Reports Q2 Loss, Misses Revenue Estimates
- Navidea (NAVB) delivered earnings and revenue surprises of 0.00% and -56.50%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- 08/11/2021
|
Navidea Biopharmaceuticals to Host Second Quarter 2021 Earnings Conference Call and Business Update
- DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will host a conference call and webcast on Wednesday, August 11, 2021 at 5:00 p.m. (EDT) to discuss financial results and corporate developments for the second quarter ended June 30, 2021. Jed Latkin, Chief Executive Officer, Dr. Michael Rosol, Chief Medical Officer
- 08/04/2021
|
NAVB Stock Increases Over 9% Pre-Market: Why It Happened
- The stock price of Navidea Biopharmaceuticals Inc (NYSEAMERICAN: NAVB) increased by over 9% pre-market. This is why it happened.
- 07/15/2021
|
Navidea Biopharmaceuticals Announces End-of-Phase 2 Type B Meeting Request Granted by the FDA to Discuss Ongoing Clinical Program in Rheumatoid Arthritis
- DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that the U.S. Food and Drug Administration (“FDA”) has granted the Company's request for an End-of-Phase 2 Type B meeting to discuss its ongoing program in Rheumatoid Arthritis (“RA”) and advancement to the pivotal Phase 3 trial. The meeting will take place on Septembe
- 07/15/2021
|
Navidea Biopharmaceuticals, Inc. (NAVB) CEO Jed Latkin on Q1 2021 Results - Earnings Call Transcript
- Navidea Biopharmaceuticals, Inc. (NAVB) CEO Jed Latkin on Q1 2021 Results - Earnings Call Transcript
- 05/11/2021
|
Navidea Biopharmaceuticals to Host First Quarter 2021 Earnings Conference Call and Corporate Update
- DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will host a conference call and webcast on Tuesday, May 11 2021 at 5:00 p.m. (EDT) to discuss financial results and corporate developments for the first quarter ended March 31, 2021. Jed Latkin, Chief Executive Officer, Dr. Michael Rosol, Chief Medical Officer, and
- 05/04/2021
|
Navidea Biopharmaceuticals, Inc. (NAVB) CEO Jed Latkin on Q4 2020 Results - Earnings Call Transcript
- Navidea Biopharmaceuticals, Inc. (NAVB) CEO Jed Latkin on Q4 2020 Results - Earnings Call Transcript
- 03/25/2021
|
Navidea Biopharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results
- DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the fourth quarter and full year for the period ended December 31, 2020. “We are very excited about the progress we have made, completing all the patients in the Phase 2B NAV3-31 trial and submitting our briefing book to the FDA were milestone
- 03/24/2021
|
Navidea Biopharmaceuticals Announces Submission of Formal Type B Meeting Request with FDA and Launch of NAV3-32 Phase 2B Trial in Rheumatoid Arthritis
- DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to announce that the Company has submitted its formal Type B Meeting Request to the FDA. The FDA has granted the Type B meeting and has requested submission of the Briefing Book. The FDA will now review the Company's formal briefing documents containing results from the NAV
- 02/08/2021
|
Navidea Biopharmaceuticals Strengthens Board of Directors with the Appointment of Malcolm Witter
- DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the appointment Malcolm G. Witter to its Board of Directors. Mr. Witter brings decades of financial and corporate governance experience to the board. He currently serves as a corporate development leader for USI Insurance Services (“USI”) and is responsible for acquiri
- 12/28/2020
|
Is Navidea Biopharmaceuticals Inc (NAVB) A Good Stock To Buy?
- Is Navidea Biopharmaceuticals Inc (NYSE:NAVB) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top investors, who employ world-class Ivy League graduates, who are given immense resources and industry contacts to put their financial expertise to work. The top picks of these firms have historically outperformed the market when we account for known risk factors, making them very valuable investment ideas.
- 11/26/2020
|
Navidea Biopharmaceuticals, Inc. (NAVB) CEO Jed Latkin on Q3 2020 Results - Earnings Call Transcript
- Navidea Biopharmaceuticals, Inc. (NAVB) CEO Jed Latkin on Q3 2020 Results - Earnings Call Transcript
- 11/12/2020
|
Navidea Biopharmaceuticals: Too Many Risks Involved
- Shares of Navidea Biopharmaceuticals have risen this year thanks to the positive results from its Phase 2 trial.
- 09/14/2020
|
Navidea Biopharmaceuticals, Inc. (NAVB) CEO Jed Latkin on Q2 2020 Results - Earnings Call Transcript
- Navidea Biopharmaceuticals, Inc. (NYSEMKT:NAVB) Q2 2020 Results Earnings Conference Call August 13, 2020, 5:00 pm ET Company Participants Jed Latkin - Chief Executive Officer, Chief Financial Officer and Chief Operating Officer Mike Rosol - Chief Medical Officer Erika Gibson - Director of Finance and Administration Conference Call Participants Michael Okunewitch - Maxim Group Vernon Bernardino - H.C.
- 08/14/2020
|
Navidea Biopharmaceuticals Reports Second Quarter and Year-to-Date 2020 Financial Results
- Navidea Biopharmaceuticals, Inc. (NYSE American:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the second quarter and year-to-date for the period ended June 30, 2020.
- 08/13/2020
|
Jubilant Radiopharma and Navidea Biopharmaceuticals Sign Binding Memorandum of Understanding for Commercialization Partnership
- Jubilant Radiopharma, a business unit of Jubilant Pharma Limited and Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) announced today that both companies have signed a binding memorandum of understanding ("MOU"). The MOU outlines the terms and framework for an Exclusive License and Distribution Agreement ("ELDA") for Navidea’s diagnostic imaging agent Tilmanocept (technetium Tc 99m tilmanocept injection) in the United States, Canada, Mexico, and Latin America. In connection with the MOU, Jubilant Radiopharma also made a $1 million equity investment in exchange for a limited exclusivity period while final due diligence efforts are completed.
- 08/10/2020
|
Navidea Biopharmaceuticals Signs Binding Framework for Commercialization Partnership with Jubilant Radiopharma
- Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to announce that it has signed a binding memorandum of understanding ("MOU") with Jubilant Draximage Inc. dba Jubilant Radiopharma, Radiopharmaceuticals Division ("Jubilant"). The MOU outlines the terms and framework for an Exclusive License and Distribution Agreement ("ELDA") for Navidea’s Rheumatoid Arthritis Diagnostic in the United States, Canada, Mexico, and Latin America.
- 08/10/2020
|
Navidea Biopharmaceuticals Signs Binding Framework for Commercialization Partnership with Jubilant Radiopharma
- Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnosti
- 08/10/2020
|
Navidea Biopharmaceuticals to Host Second Quarter 2020 Earnings Conference Call and Corporate Update
- Navidea Biopharmaceuticals, Inc. (NYSE American:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will host a conference call and webcast on Thursday, August 13, 2020 at 5:00 p.m. (EDT) to discuss financial results and corporate developments for the second quarter ended June 30, 2020.
- 08/06/2020
|
Navidea Biopharmaceuticals to Host Second Quarter 2020 Earnings Conference Call and Corporate Update
- Navidea Biopharmaceuticals, Inc. (NYSE American:NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic
- 08/06/2020
|
INVESTIGATION ALERT: Fields Kupka & Shukurov LLP Is Investigating Navidea Biopharmaceuticals, Inc. for Potential Breach of Fiduciary Duty Claims
- NEW YORK, NY / ACCESSWIRE / August 5, 2020 / Fields Kupka & Shukurov LLP is investigating potential breach of fiduciary duty claims involving the board of directors of Navidea Biopharmaceuticals, Inc.
- 08/05/2020
|
Impact of COVID-19 on the Positron Emission Tomography (PET) Market, 2020-2027 Featuring GE Healthcare, Hitachi, Neusoft, Philips Healthcare, Siemens Healthineers, Toshiba, United Imaging, and More - ResearchAndMarkets.com
|
Is the Options Market Predicting a Spike in Navidea Biopharmaceuticals (NAVB) Stock?
- Investors need to pay close attention to Navidea Biopharmaceuticals (NAVB) stock based on the movements in the options market lately.
- 06/17/2020
|
Navidea (NAVB) Gets a Buy Rating from Maxim Group - Markets
- Maxim Group analyst Jason McCarthy assigned a Buy rating to Navidea (NAVB – Research Report) today and set a price
- 06/16/2020
|
Top Stocks To Short As Coronavirus Fears Grow With Market Rally
- Retail sales surging 18% in May fared well with the markets this morning, but with growing concerns over a Coronavirus resurgence, it's clear that volatility is just around the corner. We've utilized our AI to determine which stocks are overextended and worth taking a short position.
- 06/16/2020
|
Navidea Biopharmaceuticals Announces Full Enrollment in its Ongoing Phase 2B Trial of Tc99m Tilmanocept in Rheumatoid Arthritis (RA)
- Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to announce full enrollment in its ongoing NAV3-31 Phase 2B study titled “Evaluation of the Precision and Sensitivity of Tilmanocept Uptake Value (TUV) on Tc99m Tilmanocept Planar Imaging”. All of the subjects have been enrolled in the three-arm trial, and the study is on track for the last patient to be screened, and evaluated by end of 2020. The aim of this Phase 2B study is to evaluate the repeatability, reproducibility, and stability of Tc99m tilmanocept imaging in both healthy subjects (Arm 1) and in patients with active RA (Arm 2), as well as to assess the ability of Tc99m tilmanocept to provide an early indicator of efficacy of anti-tumor necrosis factor (“TNF”) alpha treatment in RA patients (Arm 3).
- 06/15/2020
|
Navidea Biopharmaceuticals to Present at the Virtual Investor Fireside Chat Series
- DUBLIN, Ohio, June 09, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that Jed Latkin, Navidea’s Chief Executive Officer, will present at the Virtual Investor Fireside Chat Series on Tuesday, June 16, 2020 at 2:00 PM ET. A live video webcast of the fireside chat will be available on the IR Calendar page of the Investors section of the Company’s website (www.navidea.com). Immediately following the fireside chat, management will participate in an interactive Q&A; session with interested parties, allowing participants to type in questions and receive live responses.
- 06/09/2020
|
Navidea Biopharmaceuticals Announces Acceptance Of Abstract For Presentation At The European League Against Rheumatism (EULAR) Congress
|
Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at the European League Against Rheumatism (EULAR) Congress
- DUBLIN, Ohio, June 03, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to announce that the results from the Company’s first interim analysis of its ongoing NAV3-31 phase 2b clinical study will be presented as a poster at the European League Against Rheumatism (“EULAR”) Congress 2020. The aim of this interim analysis of the phase 2b study was to evaluate reproducibility and stability of imaging and to assess quantitative Tc99m tilmanocept uptake cut points that can reliably enable discrimination between joints of healthy people and RA patients.
- 06/03/2020
|
Company News for May 26, 2020
- Companies In The News Are: TTWO, XERS, SPLK, NAVB
- 05/26/2020
|
28 Stocks Moving in Tuesday's Pre-Market Session
|
71 Biggest Movers From Friday
|
Stocks close steady but post gains for the week ahead of U.S. Memorial Day holiday
- U.S. stock benchmarks end up for the week despite rising Sino-American tensions and a holiday that could test the bounds of business reopening efforts after...
- 05/22/2020
|
Mid-Afternoon Market Update: NASDAQ Turns Higher; Hewlett Packard Shares Tumble
|
HC Wainwright & Co. Maintains Buy on Navidea Biopharmaceutical, Raises Price Target to $6
|
46 Stocks Moving In Friday's Mid-Day Session
|
Mid-Day Market Update: LiveRamp Surges Following Q4 Results; Syndax Pharmaceuticals Shares Plummet
|
H.C. Wainwright Reiterates Buy On Navidea Biopharmaceuticals, Raises Price Target From $4 To $6; Says 'Interim results further support tilmanocept's potential for use in RA quantitative imaging. '
|
Mid-Morning Market Update: Markets Fall; Alibaba Earnings Beat Estimates
|
Navidea Biopharmaceuticals stock rockets toward 13-month high on heavy volume after update trial data
- Shares of Navidea Biopharmaceuticals Inc. more than doubled in very active premarket trading Friday, after the company provided upbeat data on an ongoing phase 2 trial of its treatment for rheumatoid arthritis. Trading volume topped 5.2 million shares about an hour before the open, compared with the full-day average of about 217,000 shares. The stock soared 145% ahead of the open, putting it on track to open at the highest regular-session price seen since April 2019. The company said late Thursday that preliminary results of a second interim analysis of its NAV3-31 Phase 2B study further corroborates its hypotheses that Tc99m tilmanocept imaging can provide robust, quantitative imaging in healthy controls and in patients with active rheumatoid arthritis (RA), and that this imaging can provide an early indicator of treatment efficacy in patients with active RA. The stock has rallied 13.4% over the past three months through Thursday, while the iShares Nasdaq Biotechnology ETF has gained 7.6% and the S&P; 500 has lost 11.7%.
- 05/22/2020
|
The Daily Biotech Pulse: FDA Nod For Aquestive, Tetraphase M&A Plot Thickens, Amarin's Vascepa In COVID Fray
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 21) * ADC Therapeutics SA (NYSE: ADCT) (IPOed May 15) * Allogene Therapeutics Inc (NASDAQ: ALLO) * AstraZeneca plc (NYSE: AZN) ( announced $1 billion BARDA funding for coronavirus vaccine program) * Biondvax Pharmaceuticals Ltd - ADR (NASDAQ: BVXV) * Cellectis SA (NASDAQ: CLLS) * ChemoCentryx Inc (NASDAQ: CCXI) * Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) * Cue Biopharma Inc (NASDAQ: CUE) * Fate Therapeutics Inc (NASDAQ: FATE) * Harpoon Therapeutics Inc (NASDAQ: HARP) * Horizon Therapeutics PLC (NASDAQ: HZNP) * Intellia Therapeutics Inc (NASDAQ: NTLA) * Kamada Ltd. (NASDAQ: KMDA) * Minerva Neurosciences Inc (NASDAQ: NERV) * Ovid Therapeutics Inc (NASDAQ: OVID) * Passage Bio Inc (NASDAQ: PASG)(FDA granted Rare Pediatric Disease designation to its gene therapy PBGM01 broadly for the treatment of GM1 gangliosidosis) * Soleno Therapeutics Inc (NASDAQ: SLNO) * Surface Oncology Inc (NASDAQ: SURF)Down In The Dumps (Biotech Stocks Hitting 52-week Lows May 21) * Akorn, Inc. (NASDAQ: AKRX) (filed for Chapter 11 bankruptcy) * Digirad Corporation (NASDAQ: DRAD) * Genfit SA (NASDAQ: GNFT)Related Link: These 6 Coronavirus Vaccine Candidates Are The Likeliest To Succeed, Says Morgan StanleyStocks In Focus Aquestive's Partnered Parkinson's Drug Gets FDA Nod Aquestive Therapeutics Inc's (NASDAQ: AQST) development partner Sunovion announced FDA approval for Kynmobi sublingual film - APL-130277 - for the acute, intermittent treatment of OFF episodes in patients with Parkinson's disease. The drug is expected to be available in the U.S. pharmacies in September.Following the approval, Aquestive said it plans to monetize its PharmFilm based therapies."We continue to expect that we will receive between $50 to $100 million of non-dilutive capital from the monetization, in one or a series of transactions," the company said.The stock rose 5.2% to $6.47 in after-hours trading.Syndax's Lead Breast Cancer Drug Flunks Late-stage Study Syndax Pharmaceuticals Inc (NASDAQ: SNDX) said a late-stage study that evaluated its investigational compound entinostat along with exemestane in patients with HR+, HER2- breast cancer who have progressed on a non-steroidal aromatase inhibitor did not achieve the primary endpoint of demonstrating a statistically significant overall survival benefit over hormone therapy alone.The study was conducted by ECOG-ACRIN Cancer Research Group and sponsored by the National Cancer Institute.The stock slumped 19.41% to $16.52 in after-hours trading.Tiziana To Spin-off Its Personalized Medicines Businesses TIZIANA LF SCIE/S ADR (NASDAQ: TLSA) said it intends to demerge its StemPrintER and SPARE genomics-based personalized medicine businesses into a separate company and effect a capital reduction to facilitate the spin-out and listing of StemPrintER as an independent entity.Amarin To Support Pilot Study Of Vascepa In Treating COVID-19 Amarin Corporation plc (NASDAQ: AMRN) said it supports a clinical trial to investigate the effects of its Vascepa on inflammatory biomarkers and other patient outcomes in individuals with COVID-19. The trial is sponsored by the Canadian Medical and Surgical Knowledge Translation Research Group, the company said.Separately, generic pharma company Hikma Pharmaceuticals announced its wholly-owned U.S. subsidiary Hikma Pharmaceuticals USA Inc. has received FDA approval for its generic equivalent to Vascepa.In pre-market trading Friday, Amarin stock was adding 3.85% to $7.56.Navidea Reports Positive Mid-stage Results For Rheumatoid Arthritis Treatment Navidea Biopharmaceuticals Inc (NYSE: NAVB) announced positive preliminary results from the second interim analysis of its ongoing NAV3-31 Phase 2B study"Analysis demonstrates that these interim data further corroborate Navidea's hypotheses that Tc99m tilmanocept imaging can provide robust, quantitative imaging in healthy controls and in patients with active rheumatoid arthritis, and that this imaging can provide an early indicator of treatment efficacy in patients with active RA," the company said.The stock was seen skyrocketing 65.35% to $2.10 in pre-market trading.Roche Buys Gene Sequencing Tech Company Roche Holdings AG (OTC: RHHBY) announced acquisition of Stratos Genomics, an early-stage sequencing technology company to advance the development of its nanopore sequencer.The company did not disclose the financial terms of the dealTetraphase Deems Melinta's Latest All-Cash Offer As Superior, Notifies AcelRx Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH), which has been pursued by multiple companies, said its board has determined that the latest proposal from Melinta Therapeutics, Inc. is a "Superior Offer."'Melinta has offered $27 million in cash, plus an additional $12.5 million in cash potentially payable under contingent value rights to be issued in the proposed acquisition.View more earnings on IBBTetraphase, which agreed to a deal to be bought byAcelRx Pharmaceuticals Inc (NASDAQ: ACRX), said it has informed about its determination concerning the Melinta offer and given AcelRx time until May 29 to either terminate the merger or revise the terms of the merger.Incidentally, La Jolla Pharmaceutical Company (NASDAQ: LJPC) had also tabled an offer for Tetraphase.In pre-market trading, AcelRx shares were adding 2.74% to $1.50.Amag Divests Intrarosa For Upto $125M AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) said it has completed the sale of its rights to Intrarosa to Millicent Pharma Limited, for up to $125 million, including upfront fixed consideration of $20 million and contingent, sales-based milestone payments of up to $105 million.The company said the sale is consistent with its previously announced strategic decision to divest its women's health assets. It also said it remains committed to the divestiture of Vyleesi and associated expense reductions as previously announced.Offerings ContraFect Corp Stock (NASDAQ: CFRX) said it has priced its underwritten public offering of 11.8 million shares of its common stock and related warrants to purchase 8.85 million shares. The gross proceeds from the public offering will be approximately $52.5 million, it said. All shares in the public offering are to be sold by ContraFect.In premarket trading Friday, the stock was slipping 11.87% to $4.75.Hoth Therapeutics Inc (NASDAQ: HOTH) priced its underwritten public offering of 1.82 million shares of common stock at $2.75 per share, for raising gross proceeds of $5 million. The offering is expected to close on or about May 27.The stock was slipping 5.36% to $3 in premarket trading Friday.Dynavax Technologies Corporation (NASDAQ: DVAX) priced its previously announced underwritten public offering of 14 million shares of its common stock at $5 per share. The gross proceeds to Dynavax from the offering are expected to be approximately $70. The offering is expected to close on or about May 27.The stock was retreating 10.25% to $5.08 in premarket trading Friday.PPD Inc (NASDAQ: PPD) said it upsized and finalized the terms of the offering of $500 million aggregate principal amount of 4.625% senior notes due 2025 and $700 million aggregate principal amount 5.000% senior notes due 2028. The aggregate principal amount of the notes to be issued in the offering was increased to $1.2 billion from the previously announced $700 million, the company said.In premarket trading Friday, the stock was adding 1.23% to $28.Geron Corporation (NASDAQ: GERN) said it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of its common stock in an underwritten public offering. All the securities earmarked for the offering are being sold by the company.The stock was slipping 20.92% to $1.55 in pre-market trading.On The Radar Clinical Readouts Atara Biotherapeutics Inc's (NASDAQ: ATRA) abstract on the Phase 1 data for ATA188 in multiple sclerosis, regarding its European Academy for Neurology presentation, will be made available online at 12:30 pm ET.Earnings Teligent Inc (NEW JERSEY) (NASDAQ: TLGT)IPO Inari Medical, a medical device company, priced its upsized initial public offering of 8.203 million shares of its common stock at $19.00 per share, for total gross proceeds of approximately $156 million. The company had earlier planned for a 7.33-million stock offering, with an estimated price of $17-$18 per share. The shares are to be listed on the Nasdaq under the ticker symbol NARI.See more from Benzinga * The Daily Biotech Pulse: Mixed Filgotinib Readout For Gilead-Galapagos, Akorn To File For Chapter 11, D-Day For Aquestive * The Daily Biotech Pulse: Aldeyra Jumps Into COVID-19 Drug Fray, FDA Nod For Myriad's Companion Diagnostic Test * The Daily Biotech Pulse: FDA Nod For Roche, Arbutus Releases Positive Readout For HBV Therapy, Moderna Announces .34B Common Stock Offering(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 05/22/2020
|
The Daily Biotech Pulse: FDA Nod For Aquestive, Tetraphase M&A Plot Thickens, Amarin's Vascepa In COVID Fray
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 21)
ADC Therapeutics SA (NYSE:...
- 05/22/2020
|
Navidea Biopharmaceuticals Announces Positive Results of Second Interim Analysis of Ongoing Phase 2B Study in Rheumatoid Arthritis
- Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to announce positive preliminary results from the Company’s second interim analysis of its ongoing NAV3-31 Phase 2B study. Analysis demonstrates that these interim data further corroborate Navidea’s hypotheses that Tc99m tilmanocept imaging can provide robust, quantitative imaging in healthy controls and in patients with active rheumatoid arthritis ("RA"), and that this imaging can provide an early indicator of treatment efficacy in patients with active RA.
- 05/21/2020
|
Navidea Biopharmaceuticals Announces Positive Results of Second Interim Analysis of Ongoing Phase 2B Study in Rheumatoid Arthritis
- Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnosti
- 05/21/2020
|
Edited Transcript of NAVB earnings conference call or presentation 14-May-20 9:00pm GMT
- Q1 2020 Navidea Biopharmaceuticals Inc Earnings Call
- 05/15/2020
|
Navidea Biopharmaceuticals, Inc. (NAVB) CEO Jed Latkin on Q1 2020 Results - Earnings Call Transcript
- Navidea Biopharmaceuticals, Inc. (NYSEMKT:NAVB) Q1 2020 Results Earnings Conference Call May 14, 2020, 5:00 pm ET Company Participants Jed Latkin - Chief Execut
- 05/15/2020
|
Navidea Biopharmaceuticals Reports First Quarter 2020 Financial Results
- Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the first quarter ended March 31, 2020.
- 05/14/2020
|
The Daily Biotech Pulse: ASCO Abstracts Create Stock Ripples, Applied DNA's Coronavirus Test Receives EUA, Biopharmx Shareholders Vet Reverse Merger
|
Navidea Biopharmaceuticals Reports First Quarter 2020 Financial Results
- Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnosti
- 05/14/2020
|
Navidea Biopharmaceuticals Regains Commercialization and Distributions Rights in Europe for LYMPHOSEEK®
- Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to announce that the Company has regained the commercialization and distribution rights in Europe for LYMPHOSEEK® (technetium Tc99m tilmanocept) injection from Norgine B.V. ("Norgine"). Navidea and Norgine have decided, by mutual agreement, to end the existing license agreement ("Agreement") between the two companies.
- 05/11/2020
|
Navidea Biopharmaceuticals Regains Commercialization and Distributions Rights in Europe for LYMPHOSEEK®
- Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnosti
- 05/11/2020
|
The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight
- The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB)...
- 05/10/2020
|
Navidea Biopharmaceuticals to Host First Quarter 2020 Earnings Conference Call and Corporate Update
- Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will host a conference call and webcast on Thursday, May 14, 2020 at 5:00 p.m. (EDT) to discuss financial results and corporate developments for the first quarter ended March 31, 2020.
- 05/07/2020
|
Navidea Biopharmaceuticals Provides Statement Regarding COVID-19 Pandemic
- Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announces the following statement regarding the impact of the COVID-19 pandemic on the company’s ongoing clinical development efforts:
- 04/22/2020
|
What You Must Know About Navidea Biopharmaceuticals, Inc.'s (NYSEMKT:NAVB) Beta Value
- If you own shares in Navidea Biopharmaceuticals, Inc. (NYSEMKT:NAVB) then it's worth thinking about how it contributes...
- 04/21/2020
|
Navidea Biopharmaceuticals Signs Letter of Intent with WorldCare Clinical to Partner on Navidea’s Rheumatoid Arthritis Clinical Imaging Workflow and Commercialization; Other Business Updates
- Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that it has signed a letter of intent ("LOI") to partner with WorldCare Clinical, LLC for the Company’s rheumatoid arthritis ("RA") diagnostic clinical imaging workflow. Per the agreement, WorldCare would serve as Navidea’s central imaging service provider following FDA approval of Navidea’s RA diagnostic. WorldCare Clinical is the world’s leading independent contract research organization dedicated to imaging in clinical trials and brings with it over 25 years of clinical trial imaging, commercial clinical imaging, and large-scale data management experience.
- 03/31/2020
|
Navidea Biopharmaceuticals Signs Letter Of Intent With WorldCare Clinical To Partner On Navidea's Rheumatoid Arthritis Clinical Imaging Workflow And Commercialization
|
Edited Transcript of NAVB earnings conference call or presentation 11-Mar-20 9:00pm GMT
- Q4 2019 Navidea Biopharmaceuticals Inc Earnings Call
- 03/24/2020
|
Navidea Biopharmaceuticals Announces Issuance of Patent Extension for Lymphoseek®
- Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that on March 17, 2020 the U.S. Patent and Trademark Office ("USPTO") issued a Certificate to extend the duration of U.S. patent 6,409,990 for an additional five years through May 12, 2025. This Certificate was based on the U.S. Food and Drug Administration’s ("FDA") recommendation for a five-year extension under the Hatch-Waxman Act for patent term lost in regulatory review.
- 03/20/2020
|
Navidea Biopharma Reports Issuance Of Patent Extension For Lymphoseek For Added 5 Years Through May 12, 2025
|
Navidea Biopharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results
- Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the fourth quarter and full year ended December 31, 2019.
- 03/11/2020
|
Navidea Biopharmaceuticals, Inc. to Host Earnings Call
- NEW YORK, NY / ACCESSWIRE / March 11, 2020 / Navidea Biopharmaceuticals, Inc. (AMEX:NAVB) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 11, 2020 ...
- 03/11/2020
|
The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 10) Arcutis Biotherapeutics Inc (NASDAQ: ARQT ) Aytu Bioscience Inc (NASDAQ: AYTU ) ( announced a deal to distribute COVID-19 test) Centogene NV (NASDAQ: CNTG ) Forty Seven Inc (NASDAQ: FTSV ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 10) Accelerate Diagnostics Inc (NASDAQ: AXDX ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) ADMA Biologics Inc (NASDAQ: ADMA ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Affimed NV (NASDAQ: AFMD ) Akari Therapeutics PLC (NASDAQ: AKTX ) Akcea Therapeutics Inc (NASDAQ: AKCA ) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN ) Alkermes Plc (NASDAQ: ALKS ) Allena Pharmaceuticals Inc (NASDAQ: ALNA ) ANCHIANO THERAP/S ADR (NASDAQ: ANCN ) AngioDynamics, Inc. (NASDAQ: ANGO ) ANI Pharmaceuticals Inc (NASDAQ: ANIP ) Anixa Biosciences Inc (NASDAQ: ANIX ) AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ: ANPC ) Aptevo Therapeutics Inc (NASDAQ: APVO ) Aptinyx Inc (NASDAQ: APTX ) Assertio Therapeutics Inc (NASDAQ: ASRT ) Atara Biotherapeutics Inc (NASDAQ: ATRA ) Atossa Therapeutics Inc (NASDAQ: ATOS ) Autolus Therapeutics Ltd – ADR (NASDAQ: AUTL ) AxoGen, Inc Common Stock (NASDAQ: AXGN ) Axovant Gene Therapies Ltd (NASDAQ: AXGT ) Bausch Health Companies Inc (NYSE: BHC ) Bellicum Pharmaceuticals Inc (NASDAQ: BLCM ) BENITEC BIOPHAR/S ADR (NASDAQ: BNTC ) BioLife Solutions Inc (NASDAQ: BLFS ) bluebird bio Inc (NASDAQ: BLUE ) Black Diamond Therapeutics Inc (NASDAQ: BDTX ) Capricor Therapeutics Inc (NASDAQ: CAPR ) Celcuity Inc (NASDAQ: CELC ) Cerecor Inc (NASDAQ: CERC ) Chembio Diagnostics Inc (NASDAQ: CEMI ) Eiger Biopharmaceuticals Inc (NASDAQ: EIGR ) Enochian Biosciences Inc (NASDAQ: ENOB ) Entasis Therapeutics Holdings Inc (NASDAQ: ETTX ) Eton Pharmaceuticals Inc (NASDAQ: ETON ) Evolus Inc (NASDAQ: EOLS ) Exicure Inc (NASDAQ: XCUR ) Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT ) Five Prime Therapeutics Inc (NASDAQ: FPRX ) Gossamer Bio Inc (NASDAQ: GOSS ) Gritstone Oncology Inc (NASDAQ: GRTS ) GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH ) Heron Therapeutics Inc (NASDAQ: HRTX ) Incyte Corporation (NASDAQ: INCY ) INmune Bio Inc (NASDAQ: INMB ) Integra Lifesciences Holdings Corp (NASDAQ: IART ) Invivo Therapeutics Holdings Corp (NASDAQ: NVIV ) Jaguar Health Inc (NASDAQ: JAGX ) Jazz Pharmaceuticals PLC (NASDAQ: JAZZ ) Kura Oncology Inc (NASDAQ: KURA ) Lantheus Holdings Inc (NASDAQ: LNTH ) TapImmune Inc.
- 03/11/2020
|
Navidea Biopharmaceutical Q4 EPS $(0.15) Misses $(0.12) Estimate, Sales $119.299K Down From $119.321K YoY
|
The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues
- Biotech stocks rebounded in the week ended March 6, recovering from the previous week's steep sell-off.
The week was light on news flow, barring some smid-cap earnings and...
- 03/08/2020
|
The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues
- Biotech stocks rebounded in the week ended March 6, recovering from the previous week's steep sell-off.
The week was light on news flow, barring some smid-cap earnings and...
- 03/08/2020
|
Navidea Biopharmaceuticals to Host Fourth Quarter 2019 Earnings Conference Call and Corporate Update
- Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will host a conference call and webcast on Wednesday, March 11, 2020 at 5:00 p.m. (EDT) to discuss financial results and corporate developments for the fourth quarter and full year ended December 31, 2019.
- 03/04/2020
|
H.C. Wainwright Reiterates Buy on Navidea Biopharmaceutical, Raises Price Target to $4
|
Insider Buying: John Scott Just Spent US$2.0m On Navidea Biopharmaceuticals, Inc. (NYSEMKT:NAVB) Shares
- Those following along with Navidea Biopharmaceuticals, Inc. (NYSEMKT:NAVB) will no doubt be intrigued by the recent...
- 02/21/2020
|
Navidea Biopharma Reports Regained NYSE American Compliance
|
Investors Who Bought Navidea Biopharmaceuticals (NYSEMKT:NAVB) Shares Five Years Ago Are Now Down 97%
- Navidea Biopharmaceuticals, Inc. (NYSEMKT:NAVB) shareholders will doubtless be very grateful to see the share price up...
- 02/12/2020
|
Navidea Biopharmaceuticals Obtains Partial Dismissal of Claims in New York
|
Cyclopharm (ASX:CYC) announces expansion of PET diagnostics business opportunities
- 23 Dec 2019 - Cyclopharm Limited (ASX:CYC) Managing Director and CEO, James McBrayer talks about the company's joint venture to expand Positron Emission Tomography (PET) diagnostics business opportunities for NSW and Australia.
- 12/23/2019
|
Daily Insider Ratings Round Up 12/11/19
|
Navidea Biopharmaceuticals Shares Resume Trade, Up 33% at $1.18
|
H.C. Wainwright Initiates Coverage On Navidea Biopharmaceutical with Buy Rating, Announces $3 Price Target
|
Navidea Biopharmaceuticals' (NAVB) CEO Jed Latkin on Q3 2019 Results - Earnings Call Transcript
|
Navidea Biopharmaceutical Q3 Sales $236.811K Up From $231.458K YoY
|
Navidea Biopharma Reports Results From First Interim Analysis Of Ongoing Phase 2B Study In RA: Showed Quantitative Repeatability, Stability Of Signal
|
Navidea Biopharmaceuticals (NAVB) Investor Presentation - Slideshow
|
Navidea Biopharmaceutical Q2 EPS $(0.24) Down From $(0.02) YoY, Sales $206K May Not Compare To $542.127K YoY
|
Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Friday, July 12, 2019
|
Navidea Biopharmaceuticals shares are trading higher after Maxim Group initiated coverage on the stock with a Buy rating.
|
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
|
46 Biggest Movers From Friday
|
Navidea Biopharmaceuticals shares are trading lower after the company announced a common stock offering of 8 million shares at $0.75 per share.
|
Navidea Biopharmaceuticals Reports Common Stock Offering; Size Not Disclosed
|
The Daily Biotech Pulse: Vertex Bets Big On Gene-Editing Therapies, Sanofi Poaches Novartis For CEO Role, Relief In Europe for Endologix
|
Navidea Biopharmaceutical Q1 EPS $(0.24) Up From $(0.83) YoY, Sales $136.032K Down From $276.445K YoY
|
48 Biggest Movers From Friday
|
Navidea Biopharmaceuticals Announces Comparative Study to Evaluate The Potential Utility of Tilmanocept In Patients with Tuberculosis ("TB")
|
Navidea Bio to reverse split shares 1:20
|
50 Biggest Movers From Yesterday
|
Navidea Biopharma 8-K Shows Co. Received NYSE American Notice Related To Non Compliance With $2M Minimum Shareholder Equity Requirement; Co. Has Until Apr. 15, 2019 To Be Considered For Continued Trading
|
Navidea Biopharma Reports Will Present Results Of NAV3-21 Study At SNMMI Meeting In Jun. 2019
|
Navidea Biopharmaceuticals shares are trading higher after the company announced a $3M stock purchase agreement with an existing investor.
|
Navidea Biopharma Reports $3M Private Placement
|
Daily Biotech Pulse: Allergan's Depression Drug Flunks Late-Stage Trial, Apellis Offering, ShockWave Medical IPO
|
Patterson Companies Sees FY19 Adj. EPS $1.40-$1.45
|
Navidea Biopharma Reports Extension Of NYSE American Listing Until Mar. 31, 2019 To Regain Compliance
|
Navidea Biopharma Announces the Ohio Supreme Court has Dismissed a Petition Filed by Capital Royalty Partners
|
Navidea Biopharma Reports Patent Extension For Lymphoseek For Added 5 Yers To May 12, 2025
|
Recent Analysis Shows Aquantia, Ubiquiti Networks, Reliv' International, Permian Basin Royalty ...
|
Navidea Biopharmaceutical Q3 EPS $(0.02) Down From $(0.01) YoY, Sales $231.458K Up From $223.669K YoY
|
Navidea Biopharma Shares Resume Trade, Now Up 4%
|
Navidea Biopharmaceuticals Reportes Court Dismisses Claims Against Co. By Platinum-Montaur Life Sciences
|
Navidea Biopharmaceuticals Receives Acceptance Letter from NYSE American, Common Stock Will Continue To Be Listed
|
60 Biggest Movers From Yesterday
|
22 Stocks Moving In Tuesday's Pre-Market Session
|
Navidea Biopharmaceuticals shares are up 16.3% after the company reported acceptance into the National Institutes of Health Commercialization Accelerator Program.
|
Stocks Which Set New 52-Week Low Yesterday, August 16th
|
Stocks Which Set New 52-Week Low Yesterday, August 15th
|
Navidea Biopharmaceuticals' (NAVB) Interim CEO Jed Latkin on Q2 2018 Results - Earnings Call Transcript
|
Navidea Biopharmaceuticals Receives Listing Noncompliance Notice from NYSE
|
Navidea Biopharm reports Q2 results
|
Navidea Biopharmaceutical Q2 EPS $(0.02), Same YoY, Sales $542.127M Up From $611.599K YoY
|
Navidea Biopharmaceuticals' (NAVB) CEO Michael Goldberg on Q1 2018 Results - Earnings Call Transcript
|
Navidea Biopharmaceutical Q1 EPS $(0.04), Made $276.445K Sales
|
Navidea Biopharma Reports Deal To Sublicense NAV4694 Global Development Rights
|
Navidea Biopharmaceuticals Reports Q4 EPS $(0.03) vs $(0.02) In Prior Year Period, Sales $395K vs $1.03M In Prior Year Period
|
Navidea Biopharma 8-K Shows Co. Entered Settlement Deal With Sinotau; Both Cos. Agreed To Stipulate To The Voluntarily Dismissal Of All Claims, No Other Terms Disclosed
|
Navidea Biopharm (NAVB) Presents At 10th Annual Biotech Showcase 2018 - Slideshow
|
Cardinal Health: A Dividend Aristocrat The Risk Is Already Priced In-Part 2 Of 7
- Cardinal Health Inc. (CAH) is a Dividend Aristocrat that has increased its dividend for 32 consecutive years and is currently yielding 3.3%.
- 11/22/2017
|
Navidea Biopharma Reports Q3 EPS $(0.01) vs. $0.00 In Same Qtr. Last Year, Sales $224K vs. $1.8M YoY
|
Navidea Reports Launch Of LYMPHOSEEK In Europe
|
UPDATE: Navidea Says Paid to Ricardo Gonzalez Total of ~$617.88K
|
Navidea Biopharmaceuticals Reports Q1 EPS $0.52 vs $(0.02) In Prior Year Period
|
Navidea Reports Q4 EPS $(0.02) vs $(0.02) in Same Qtr. Last Year, Sales $3.4M
|
Navidea Biopharma Files Non-Timely 10-K
|
Navidea shareholders OK sale of Lymphoseek sale to Cardinal; shares up 29%
|
Navidea Shares Resume Trade
|
Financial Advisory Group Buys iShares 7-–… Year Treasury Bond, Berkshire Hathaway Inc, ...
|
12 Biggest Mid-Day Gainers For Friday
|
Navidea Biopharma Resumes Trading, Now Up 4.59%
|
